Cholinesterase Inhibition Strategies for Alzheimer's Disease

Cholinesterase inhibition remains a cornerstone of symptomatic therapy for Alzheimer’s disease, targeting the enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) to restore cholinergic tone in the central nervous system. Early-generation inhibitors such as tacrine, donepezil, rivastigmine and galantamine exert their effects by binding to the catalytic anionic site within a deep active-site gorge, slowing acetylcholine hydrolysis and enhancing synaptic signalling. Advances in structural biology have revealed a peripheral anionic site that can be co-targeted to produce multisite inhibitors with significantly increased affinity and duration of action. Selective BChE inhibition has emerged as a strategy for later stages of the disease, when BChE activity rises and AChE declines. Modern design approaches incorporate molecular hybridisation, fragment-based assembly and computational docking to create compounds that span both binding sites or combine cholinesterase inhibition with anti-amyloid, antioxidant or anti-inflammatory functions. Emphasis on blood–brain barrier permeability, reversible binding modes and minimised off-target toxicity guides the translation of lead compounds into clinical candidates. As understanding of enzyme structure, kinetics and non-cholinergic roles deepens, next-generation inhibitors promise improved cognitive benefit and disease-modifying potential across diverse patient populations.

Research from Nature Portfolio

Potent reversible inhibitors of human butyrylcholinesterase have been developed with nanomolar affinity, guided by high-resolution crystal structures that elucidate the precise binding orientation within the active gorge. These compounds exhibit favourable blood–brain barrier penetration, non-cytotoxic profiles and significant improvement of memory and learning in cholinergic-deficit mouse models without acute cholinergic side effects. Structural insights established a framework for lead optimisation towards advanced drug candidates.

A series of hydroxylated 2-phenylbenzofuran derivatives was synthesised and evaluated for dual cholinesterase inhibition. Two lead molecules displayed micromolar potency against BChE with marked selectivity over AChE, alongside antioxidant activity. Computational simulations revealed key interaction networks within the enzyme gorge, guiding rational structural modifications to enhance binding specificity and neuroprotective properties.

Cholinesterase Inhibition Strategies for Alzheimer's Disease publication trend

The graph below shows the total number of articles in cholinesterase inhibition strategies for alzheimer's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Acetylcholinesterase (AChE): A serine hydrolase that rapidly hydrolyses acetylcholine at cholinergic synapses, terminating neurotransmission.

Butyrylcholinesterase (BChE): A related enzyme with broader substrate specificity, whose activity increases in later stages of Alzheimer’s disease.

Active-site gorge: A deep, narrow channel leading to the catalytic anionic site within cholinesterase enzymes where substrates and inhibitors bind.

Catalytic anionic site (CAS): The pocket at the base of the active-site gorge responsible for acetylcholine hydrolysis.

Peripheral anionic site (PAS): A secondary binding region near the gorge entrance that influences substrate orientation and non-cholinergic interactions.

Molecular hybridisation: A design strategy combining distinct pharmacophores to yield multisite inhibitors that engage multiple enzyme subsites.

Blood–brain barrier (BBB): The physiological barrier regulating passage of molecules from the bloodstream into the central nervous system.

References

1. Acetylcholinesterase: A Versatile Template to Coin Potent Modulators of Multiple Therapeutic Targets. Accounts of Chemical Research (2024).
2. New Acetylcholinesterase Inhibitors for Alzheimer′s Disease. International Journal of Alzheimer's Disease (2011).
3. Development of an in-vivo active reversible butyrylcholinesterase inhibitor. Scientific Reports (2016).
4. Novel 2-pheynlbenzofuran derivatives as selective butyrylcholinesterase inhibitors for Alzheimer’s disease. Scientific Reports (2018).